Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1 -Related Breast Cancers
- 1 August 2004
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (15) , 5051-5053
- https://doi.org/10.1158/0008-5472.can-04-1283
Abstract
Tumor-associated mutants of the p53 tumor suppressor protein exert biological activities compatible with an oncogenic gain of function. To explore the underlying molecular mechanism, we performed microarray analysis, comparing p53-null cells to mutant p53-expressing cells. One of the genes up-regulated in the presence of mutant p53 was EGR1, a transcription factor implicated in growth control, apoptosis, and cancer. EGR1 induction by various types of stress is markedly augmented in cells expressing mutant p53. Moreover, chromatin immunoprecipitation analysis indicates that mutant p53 is physically associated with the EGR1 promoter. Functional assays indicate that induction of EGR1 by mutant p53 contributes to enhanced transformed properties and resistance to apoptosis. We propose that EGR1 is a significant contributor to mutant p53 gain of function.Keywords
This publication has 21 references indexed in Scilit:
- BRCA2 Is Inactivated Late in the Development of Pancreatic Intraepithelial Neoplasia: Evidence and ImplicationsThe American Journal of Pathology, 2000
- Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2Oncogene, 1999
- Estrogen Receptor-Positive Proliferating Cells in the Normal and Precancerous BreastThe American Journal of Pathology, 1999
- Low oestrogen receptor α expression in normal breast tissue underlies low breast cancer incidence in JapanThe Lancet, 1999
- BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected CellsScience, 1999
- Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary glandBreast Cancer Research and Treatment, 1999
- Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriersThe Lancet, 1998
- Tumour biological features of BRCA1-induced breast and ovarian cancerEuropean Journal Of Cancer, 1997
- Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.American Journal of Public Health, 1996
- Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breastInternational Journal of Cancer, 1991